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ABSTRACT
Egg white proteins (EWP) were hydrolyzed with four proteolytic enzymes, including Thermolysin, Alcalase, Esperase and
Chymotrysin, to produce hydrolysates with angiotensin I-converting enzyme (ACE) inhibitory activity. The result indicated that
EWP hydrolyzed for 0.5-24 hr with Thermolysin produced the highest ACE inhibitory activity among the four enzymes. Therefore,
EWP-Thermolysin hydrolysate was produced and further fractionated using several membranes with molecular weight cut-off
(MWCO) of 10,000, 3,000 and 1,000 daltons, sequentially. The 1 kDa permeate obtained from the hydrolysate treatment using
1,000 daltons MWCO membrane could further reduce its IC50 value from 54.1 to 17.2 µg protein/mL. A lower IC50 value represented higher ACE inhibitory activity. The operation stability study showed that the membrane reactor system could maintain a steady
production of EWP-Thermolysin hydrolysate over 8 hr. The gastrointestinal protease in vitro effect on the ACE inhibitory activity
of 1 kDa permeate indicated that gastrointestinal proteases have no significant effect (p > 0.05) on the ACE inhibitory activity of 1
kDa permeate.
Key words: egg white proteins, ACE inhibitor, hydrolysate, peptide, membrane reactor

INTRODUCTION
Hypertension is functionally related to the angiotensin I-converting enzyme (ACE) (EC 3.4.15.1). This
enzyme plays a key physiological role in blood pressure
control by virtue of the renin-angiotensin system. ACE
cleaves to the C-terminal of the histidyl-leucine of the
inactive decapeptide angiotensin I to form octapeptide
angiotensin II, a potent vasoconstrictor. ACE also inactivates the vasodilating nonapeptide bradykinin (1). Therefore, ACE inhibition with its inhibitor reduces the angiotensin-II activity but increases bradykinin levels, and
thus can result in lowered blood pressure (2).
Enzymatic hydrolysis of food proteins, such as
casein, zein, fish protein and gelatin that release ACE
inhibitors as potential nutraceuticals, have been extensively studied (3-5). However, only few egg proteinderived peptides have been described. Miguel et al.
(2004) produced peptides with ACE inhibitory activity
from the enzymatic hydrolysis of egg white proteins (6).
These peptides were derived mainly from the ovalbu* Author for correspondence. Tel: +886-4-23506747;
Fax: +886-4-23506747; E-mail: tct1@thu.edu.tw

min proteolysis. They concluded that egg white protein
hydrolysis with pepsin to obtain a fraction having a
molecular weight lower than 3,000 daltons would produce
the highest ACE inhibitory activity in vitro. Yoshii et al.
(2001) obtained oligopeptides of 1,000 daltons or less
with ACE inhibitory activity in vitro from chicken egg
yolk hydrolysate using a crude enzyme and dialysis with
a semi-permeable membrane filter (7). They also proved
oral administration of the oligopeptides for 12 weeks
could suppress hypertension development in spontaneously hypertensive rats.
Enzymatic hydrolysis is very costly in conventional
batch-type operations because large quantities of enzymes
are required and the enzyme cannot be reused(8,9). Other
disadvantages of batch process also have been reported
such as time-consuming, labor-intensive, low yield, low
productivity and inconsistent quality(10-13). The development and application of ultra-filtration membrane reactor
for the hydrolysis of proteins has been applied to overcome those problems(14). Several studies have concluded that protein hydrolysate production in a continuous
membrane reactor results in higher productivities(15-17)
and more uniform products(14,18) than batch-type reactors.
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The objectives of this research were to screen both
proper enzyme and ultra-filtration membrane to apply
in a continuous membrane reactor for EWP hydrolysate
production with ACE inhibitory activity and evaluate the
membrane reactor performance for hydrolysate production.
The product quality was determined by measuring its IC50
of the ACE inhibitory activity during processing followed
by the effects of hydrolysis of the gastric proteases.

MATERIALS AND METHODS
I. Enzymes and C
Crude dried egg white proteins (from chicken egg
white), chymotrypsin (40-60 units/mg protein), pepsin
(800-2500 units/mg protein), pancreatin, Thermolysin
(84 units/mg protein), angiotensin-I converting enzyme
(ACE) (10 units/mg protein), and hippuryl-L -histidylL-leucine (HHL) were purchased from Sigma Chemical
Co. (St. Louis, MO, USA). Pancreatin contains many
enzymes including amylase, trypsin, lipase, ribonuclease
and protease. HPLC standards including cytochrome c,
aprotinin, substance P, (glycine)6, (glycine)3 and glycine
with molecular weight 125,000, 6,500, 1,348, 360, 189
and 75 daltons, respectively, were purchased from
Merck (Damdstadt, Germany) or Sigma Chemical Co.
(St. Louis, MO, USA). Esperase type F (7.5 units/g) and
Alcalase\ 2.4 L (2.4 units/g) were purchased from NOVO
Industry A/S (Copenhagen, Denmark). Polyethersulfone
spiral-wound membranes with molecular weight cut-off
1-10 kDa and with membrane area 0.2 m 2 were purchased
from Osmonics Inc. (California, USA).
II. Preparation of Egg Wwhite Protein (EWP) Hydrolysates
The 1.0% (w/v) EWP and 1.0% (w/w of EWP) protease were employed to produce and compare of each
hydrolysate with ACE inhibitory activity. The proteases
employed in this study included Thermolysin, Alcalase,
Esperase and Chymotrypsin. The optimum temperature and pH, reaction conditions for each enzyme were
suggested by the supplier. The temperature and pH were
adjusted to 55°C and 7.5 for Alcalase, 60°C and 8.0 for
Thermolysin and Esperase, and 37°C and 7.5 for Chymotrypsin, respectively. Samples withdrawn at 0.5, 1, 2, 4, 6,
8, 24 hr from each proteolytic mixture were immediately
heated in a boiling water bath for 10 min. The degree
of hydrolysis (DH) and ACE inhibitory activity of each
sample were determined. The DH at designated time
was measured using the orthophthaldialdehyde (OPA)
method (19).
III. Assay for ACE Inhibitory Activity
ACE Inhibitory activity was analyzed spectrophotometriclly using hippury-L-histidyl-L-leucine (HHL) as

substrate (20). Five millimolar HHL was prepared with 0.1
M sodium borate buffer (pH 8.3) containing 0.4 M NaCl.
ACE from rabbit lungs was dissolved in the same buffer
at a concentration of 60 mU/mL. A mixture containing
45 µL of HHL solution and 5 µL of protein hydrolysate
or the buffer (control) was incubated at 37°C for 5 min.
The 15 µL of ACE solution was then added and incubated
for 30 min. The reaction was stopped with 65 µL of 0.1%
trifluoroacetic acid (TFA). Hippuric acid (HA) liberated
using ACE was determined by RP-HPLC on a LiChrospher C18 column (4 × 250 mm, Merck, Germany). The
mobile phase was 0.1% TFA in 50% methanol with a flow
rate of 0.8 mL/min. The effluent was monitored with an
ultraviolet detector (Shimadzu Co., Kyoto, Japan) at 228
nm. The IC50 value was defined as the ACE inhibitor
or protein hydrolysate concentration needed to reduce
50% of the height for the HA peak, and determined by
regression analysis of ACE inhibitory activity (%) versus
protein concentration. The IC50 value was expressed in
terms of mg protein/mL. ACE inhibitory activity (%)
was expressed as
ACE inhibitory activity (%) =

Ho - Hp
Ho

× 100

(1)

where Ho = height for HA peak without protein hydrolysate;
Hp = height for HA peak with protein hydrolysate.
IV. Fractionation of Hydrolysates with Ultra-filtration
Membranes
Hydrolysates generated from the enzymatic hydrolysis of chicken egg EWP were subjected to ultra-filtration using a spiral-wound membrane with 10 kDa, 3 kDa
and 1 kDa molecular weight cut-off, sequentially. Each
permeate was collected to determine its protein concentration, profile of molecular weight distribution, and IC50
for ACE inhibitory activity.
V. Batch Reactor
The batch reactor consisted of a reaction vessel (1 L)
with hot water jacket and stirring arm to provide uniform
heating and mixing. About 0.5 to 1 L of 1% EWP solution
was introduced into the reaction vessel and heated. Until
the solution reached the desired temperature, 1% of enzyme
/ substrate (w/w) was added into the reaction vessel.
VI. Membrane Reactor System
One percent of EWP solution was prepared by vigorously stirring and heating while passing through a 100mesh sieve to remove large particles. The reaction vessel
with jacket (Figure 1) was filled with the desired volume
of 1% EWP filtrate and the tank temperature was maintained at 50°C using Neslab circulator unit (Thermo,
USA). One percent of enzyme (w/w of substrate) was
added into the EWP filtrate. The inlet pressure and flow
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Figure 1. Schematic diagram of continuous spiral-wound membrane
reactor system.

rate were adjusted properly. The reaction mixture was
pumped to the spiral-wound membrane module with an
inlet pressure of 4 kg/cm 2 , where large particles such
as intact proteins or enzymes could not penetrate the
ultra-filtration membrane pores. These large particles
would be recycled into the reaction vessel. The permeate containing particles small enough to penetrate the
membrane was collected and lyophilized. The level of
reaction mixture in the vessel was controlled by adjusting
the flow rates between the EWP solution from the feed
tank and the permeate from the membrane.
VII. Total Nitrogen
Total nitrogen was measured using the micro-Kjeldahl method (21) using a KjelTec system 1026 with a
rapid distillation unit (Tecator, Sweden). All data were
corrected for nonprotein nitrogen (NPNi), which was
determined as the initial EWP soluble nitrogen in 10%
trichloroacetic acid (TCA). The TCA-soluble nitrogen in
the product (NPNp) was also determined. The % TCA
soluble nitrogen or % conversion X was expressed as
X (%) =

NPNp - NPNi
TN - NPNi

× 100

(2)

VIII. Productivity Study(22)
For the batch reactor, productivity was defined as
XTNi
E

(4)

(5)

where PI = instantaneous productivity; P = average product output (mg N/mL) in a time period t (min); J = flow
rate (mL/min); E = enyzme concentration (mg/mL); V
= substrate volume (L); Pc = cumulative productivity.
Pc was calculated over all periods studied. The unit of
productivity was mass hydrolysate/ mass enzyme (mg N/
mg enzyme).
IX. Molecular Weight Distribution
The molecular weight distribution of the hydrolysate was analyzed using high-performance size-exclusion
chromatography (HPSEC). The HPSEC was equipped
with Superdex HR 10/30 column (Amersham Biosciences
Ltd., Pittsburgh, PA., USA) connected to an UV detector
(Shimadzu Co., Kyoto, Japan) set at 214 nm. The mobile
phase was 0.02 M phosphate buffer (pH 7.2) containing
0.25 M NaCl and flow rate was set at 0.5 mL/min.
X. Stability Study
The stability against in vitro gastric proteases was
assessed as followed(23). One percent (w/v) of EWP hydrolysate was treated in 0.1 M KCl-HCl (pH 2.0) buffer with
pepsin for 4 hr in a water bath at 37°C. The reaction was
stopped by boiling in a water bath for 15 min and neutralized to pH 7.0 with the addition of 2N NaOH solution.
One milliliter of neutralized suspension was centrifuged
(10,000 ×g, 40min) and the supernatant was used for ACE
inhibitory activity determination. The remaining neutralized suspension was digested further by 2% (w/w) pancreatin at 37°C for 4 hr. The enzyme was inactivated by
boiling for 15 min followed by centrifugation. The supernatant was used for ACE inhibitory activity determination.

RESULTS AND DISCUSSION
I. Effect of Different Protease Hydrolysis on ACE
Inhibitory Activity

where TN = total nitrogen in the product.

Pbatch =

EV

or

Outlet Pressure
Meter & Controller

Flow Rate Controller

P Jt

(3)

where E = enzyme concentration (mg/mL); TNi = total
nitrogen in unhydrolyzed substrate corrected for NPNi.
For continuous HF membrane reactor, productivity
was expressed as

Egg white proteins (EWP) were hydrolyzed using
Thermolysin, Alcalase, Esperase and Chymotrypsin for
0.5-24 hr, respectively. Figure 2 shows the ACE inhibitory activity and the degree of hydrolysis (DH) in comparison of the four enzyme hydrolysates as a function of the
hydrolysis time. Both DH and ACE inhibitory activity
increased with the increase in hydrolysis time for each
enzyme. The graphs clearly showed that enzymatic hydrolysis was required to release ACE inhibitory peptides from
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ACE inhibitory activity (%)

80

Thermolysin
Alcalase

60

Esperase

50

Table 1. The peptide content, yield and IC50 value of the egg white
protein hydrolysate (EWPH) and its permeates, filtered by different
molecular weight cut-off membranes in a membrane reactor system

Chymotrypsin

Sample*

40
30

Peptide content
(mg protein/mL)

Peptide
yield
(%)

IC50
(µg protein/
mL)**

20

EWPH

7.95

100

54.1a

10

10 kDa permeate

5.98

76.2

35.1b

3 kDa permeate

3.73

48.8

22.6c

1 kDa permeate

3.04

39.6

17.2d

0

Degree of hydrolysis (%)

(A)

70

0

70

2

4

6

8

(B)

10
Thermolysin

60

Alcalase

50

Esperase

40

Chymotrypsin

*EWPH filtered by a membrane module with 10 kDa, 3 kDa or 1 kDa
MWCO, denoted as 10 kDa, 3 kDa or 1 kDa permeate, respectively.
**It is significantly different (p < 0.05) with different letter.
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Figure 2. Comparison of (A) ACE inhibitory activity; and (B) degree
of hydrolysis (DH) within four enzyme hydrolysates as a function
of hydrolysis time. Each hydrolysate was diluted 10 times befor
measurement of the inhibitory activity. Results are mean values of
at least two replicates. Standard deviation did not exceed 3% of the
recorded values. The reaction conditions of temperature and pH were
adjusted to 55°C and 7.5 for Alcalase, 37°C and 7.5 for chymotrypsin,
60°C and 8.0 for Thermolysin and Esperase, respectively.

10 kDa

10 kDa permeate

3 kDa permeate

1 kDa permeate

the inactive form of intact EWP. After 2-4 hr of hydrolysis, all enzymes had steady ACE inhibitory activity.
Thermolysin showed the highest ACE inhibitory activity
and DH among the four enzymes. Thermolysin also had
the best ACE inhibitory activity in terms of IC50 with the
value of 54.1 µg protein/mL at steady state as compared
with the IC50 value of 78.8, > 750 and >750 µg protein/mL
for Chymotrypsin, Alcalase and Esperase, respectively.
The lower IC50 represented higher ACE inhibitory activity. Therefore, Thermolysin was selected for further study
on enzymatic production of ACE inhibitor from EWP.
Thermolysin is a bacterial protease that has been studied
to hydrolyze porcine skeletal muscle protein, bonito and
lactoglobulin to produce ACE inhibitor (24-26).
II. Effect of Different Ultra-filtration Membranes on ACE
Inhibitory Activity
EWP hydrolysates (EWPH) were prepared by hydrolysis of 1.0% EWP with 1.0% Thermolysin at 60°C and
pH 8.0 for 2 hr, heating in a boiling water bath for 10 min,
and then centrifugation at 10,000 ×g for 10 min. The
EWPH was collected for further study on ACE inhibitory
peptides fractionation using spiral-wound membranes.
Table 1 shows the peptide content, peptide yield and

Figure 3. The molecular weight distribution of egg white protein
hydrolysate (EWPH) and its retentates and permeates obtained from
the membrane reactor with different MWCO membranes.

ACE inhibitory activity IC50 of each permeate obtained
by ultra-filtering EWPH with 10, 3 and 1 kilo-daltons
(kDa) molecular weight cut-off (MWCO) membranes,
sequentially. The ACE inhibitory activities and peptide
yield of the permeates increased with the decrease in
MWCO. The 1 kDa permeate obtained from EWPH
treatment using 1,000 daltons MWCO membrane could
further reduce its IC50 value from 54.1 to 17.2 µg protein/
mL. Therefore, 1 kDa MWCO membranes were further
applied for continuous ACE inhibitor production.
Figure 3 shows the molecular weight distribution of
EWPH and its retentates and permeates obtained from
the membrane reactor with different MWCO membranes.
By examining the 10 kDa permeate profile, the 10 kDa
MWCO membrane could eliminate all peptides with
a molecular weight (MW) greater than 6.5 kDa in the
EWPH. Furthermore, the 3 kDa and 1 kDa permeate profiles also showed that 3 kDa and 1 kDa MWCO
membranes could further remove peptides with MW
greater than 1.5 kDa and 0.4 kDa, respectively. These
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results indicated that the membrane module was very
effective in fractionating EWPH into smaller peptide
fractions. The smaller MWCO membrane resulted in the
lower IC50 value (Table 1). The results also implied that
peptides with MW less than 0.4 kDa were responsible for
the major ACE inhibitory activity in the EWPH.
Tryptic casein hydrolyaste with an IC50 value of 166
µg protein/mL had been reported to have an antihypertensive effect in spontaneously hypertensive rats (27). The
IC50 values obtained from ultra-filtered tryptic digests
of milk protein ranged from 130-201 µg protein/mL
expressed the potential to apply such protein hydrolysates
as nutraceuticals in the prevention of hypertension(28).
Furthermore, single oral administration of royal jelly
protein hydrolysates with an IC50 value of 99 µg protein/
mL in 10-week spontaneously hypertensive rats resulted
in a significant reduction in systolic blood pressure (29).
Therefore, the IC50 values for ultra-filtered EWPH reported herein were even below the concentration range and
likely to mediate an anti-hypertensive effect (Table 1).
III. Continuous Spiral-wound (SW) Membrane Reactor
Both productivity and operation stability of continuous SW membrane reactors were evaluated using a 1 kDa
MWCO membrane. Figure 4 illustrates a productivity
comparison between batch and continuous reactors as a
function of the volume replacement. The productivity of
the batch reactor was independent of the volume replacement, whereas the continuous SW membrane reactor
had a direct linear relationship with the volume replacement. This was because that each volume replacement
(1 L) required the same amount of enzyme in the batch

reactor. However, in the continuous SW membrane reactor the enzyme was introduced only once at the beginning of the run. After three volume replacements, the
continuous membrane reactor had a higher productivity
than the batch reactor. The result indicated that reusing
the enzyme had the advantage of higher productivity in
the continuous membrane reactor. Several studies also
agreed with these findings (16,18,30).
Figure 5 shows the operation stability of the continuous membrane reactor system in terms of product output
and IC50. The continuous SW membrane reactor showed
steady protein hydrolysate production after a 6 hr operation. There was no detectable enzyme leakage within 8 hr
using residue activity detection in the permeate (data not
shown). At any operation time the IC50 of each permeate
from the continuous SW membrane reactor maintained its
inhibitory activity below 18 µg protein/mL.
Since some food-protein-derived ACE inhibitors
failed to express hypotensive activity after oral administration in vivo(4), the mixture of 1 kDa permeates collected
from the continuous membrane reactor was investigated
for its ACE inhibitory activity in vitro by treatment with
gastrointestinal proteases including pepsin and the combination of pepsin and pancreatin, respectively. Gastric in
vitro incubation has been reported to provide a practical and easy process, imitating the fate of these peptides
after oral administration(23). Table 2 shows the effects of
gastrointestinal proteases on ACE inhibitory activity of 1
kDa permeate in vitro. The result indicated that gastrointestinal protease had very little effect (p < 0.01) on the
ACE inhibitory activity of the mixture of 1 kDa permeates. Therefore, the result suggested that peptides in 1 kDa
permeate be resistant to digestion. Several other reports
also have concluded that small peptides had low susceptibility to hydrolysis by gastric proteases(7,23,31).
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Figure 4. Comparison of productivity between batch reactor and
membrane reactor. Results are mean values of at least two replicates.
Standard deviation did not exceed 4% of the recorded values.
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Figure 5. Operation stability of the continuous membrane reactor
system in terms of product output and IC50. Results are mean values
of at least two replicates. Standard deviation did not exceed 4% of the
recorded values.
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Table 2. ACE inhibitory activity of 1 kDa permeate followed by
digestion using gastrointestinal proteases
Enzyme

IC50 (µg protein/mL)*

Control (1 kDa permeate)

17.2a

Pepsin

17.0a

Pepsin + pancreatin

16.5a

*It is not significantly different (p > 0.05) with same letter.

CONCLUSIONS
The results from this study showed that it was possible to continuously produce EWPH with ACE inhibitory
activity in a membrane reactor. The major advantages of
the membrane reactor over the traditional batch reactor
were the large increase in enzyme utilization efficiency
and overall reactor productivity. By selecting the optimum MWCO membrane a consistently uniform product
with the desired molecular weight characteristics could
be achieved. The 1 kDa permeate with IC50 less than
18 µg protein/mL obtained from the membrane reactor
might represent a potential nutraceutical for the prevention of hypertension. However, further confirmation
of the efficacy of this nutraceutical on blood pressure
decrease in spontaneously hypertensive rats or in clinically hypertensive human subjects is required.
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